Bloomington, Indiana-based Cook begins assuming sales management and marketing responsibilities for PillSense in the fourth quarter, the company announced yesterday.
The company says its distribution agreement allows it to collaborate with other companies. Now, Cook Medical can offer the PillSense technology to its customers.
EnteraSense designed PillSense as a novel blood-sensing system. After a patient swallows the capsule device, it accurately detects upper gastrointestinal bleeding (UGIB). The device, which won FDA approval in February 2023, can provide fast diagnosis and appropriate triaging.
“GI bleeds can be life-threatening. The sooner physicians can diagnose a bleed, the better chance a patient has of survival,” said Meurisse Leahy, director of product management for Cook’s Endoscopy specialty. “Physicians can combine PillSense with our Hemospray and Instinct Plus products to both diagnose and treat gastrointestinal bleeds faster. Through this distribution partnership, we’re excited to expedite delivery of this unique product to healthcare providers.”
“The innovative PillSense system can transform how UGIB patients are diagnosed and deliver significant benefits to patients, clinicians and hospitals. This strategic partnership between EnteraSense and Cook Medical will accelerate the availability of PillSense right across the U.S.,” said Donal Devery, CEO, EnteraSense.
